Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Awareness Rate for CKD only 10%: Healthclick
April 6, 2009
- Daiichi Sankyo Sues 13 Companies for Levofloxacin Patent Violation
April 6, 2009
- JSMO Aims at Health Insurance Coverage of KRAS Gene Testing
April 6, 2009
- Many Patients Hesitate to Request Generic Substitution
April 6, 2009
- Synergism with Millennium to Drive Takeda's Business in Oncology
April 6, 2009
- 12 Drugs and 5 APIs Priced
April 6, 2009
- Falsification of Data Found on World's 1st Recombinant Human Albumin
April 6, 2009
- Tanaka Kikinzoku Develops Flu Virus Detection Reagent Using Gold Particles
March 30, 2009
- Mr Ishii of JPA Rages at Mr Mikitani
March 30, 2009
- Asubio Pharma to Specialize in Drug Discovery
March 30, 2009
- RDKK to Enhance Focus on Prediction of Efficacy of Anticancer Drugs
March 30, 2009
- BUSINESS NEWS IN BRIEF
March 30, 2009
- Drugs Eligible for Price Maintenance Must Be Strictly Selected: Chuikyo
March 30, 2009
- FPMAJ Should Maintain Its Stance Regarding Range of Drugs Eligible for Price Maintenance System: Mr Nagano
March 30, 2009
- Industry Proposes to Create Organization to Develop Unapproved Drugs
March 30, 2009
- REGULATORY NEWS IN BRIEF
March 30, 2009
- Dispensing Fees Will Be Cut if Use of Generics Does Not Increase: Mr Urushibata
March 30, 2009
- GENERICS NEWS IN BRIEF
March 30, 2009
- The First Round Results of GE Amlodipine (1) - Making No Surprise Moves Leads to Success -
March 30, 2009
- Astellas to Enhance Its Presence as "National Flag Pharma"
March 30, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…